Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 539,905
  • Shares Outstanding, K 46,304
  • Annual Sales, $ 8,780 K
  • Annual Income, $ -104,700 K
  • 60-Month Beta 0.77
  • Price/Sales 59.33
  • Price/Cash Flow N/A
  • Price/Book 3.15
Trade STOK with:

Options Overview Details

View History
  • Implied Volatility 108.70% ( +5.33%)
  • Historical Volatility 169.95%
  • IV Percentile 49%
  • IV Rank 22.04%
  • IV High 312.96% on 07/14/23
  • IV Low 50.95% on 11/13/23
  • Put/Call Vol Ratio 0.56
  • Today's Volume 469
  • Volume Avg (30-Day) 1,388
  • Put/Call OI Ratio 1.52
  • Today's Open Interest 3,586
  • Open Int (30-Day) 10,065

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.60
  • Number of Estimates 5
  • High Estimate -0.54
  • Low Estimate -0.70
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -13.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.29 +85.37%
on 03/25/24
16.40 -28.90%
on 03/27/24
+5.36 (+85.08%)
since 03/22/24
3-Month
4.09 +185.09%
on 02/13/24
16.40 -28.90%
on 03/27/24
+6.89 (+144.44%)
since 01/24/24
52-Week
3.35 +248.06%
on 10/27/23
16.40 -28.90%
on 03/27/24
+3.56 (+43.95%)
since 04/24/23

Most Recent Stories

More News
Stocks Inch Higher After February's US Durable Goods Orders Released

Stocks are slightly up this morning as market participants reacted to February's US Durable Goods Report.

$SPX : 5,071.63 (+0.02%)
SPY : 505.41 (-0.05%)
$DOWI : 38,460.92 (-0.11%)
DIA : 384.44 (-0.15%)
$IUXX : 17,526.80 (+0.32%)
QQQ : 426.51 (+0.34%)
TTWO : 142.83 (+0.78%)
UAL : 52.67 (-2.52%)
MCD : 276.75 (-0.05%)
DIS : 113.92 (+0.18%)
OCDO.LN : 365.700 (+0.30%)
STOK : 11.66 (+3.64%)
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street

This small-cap biotech might be a hidden gem.

ACAD : 16.59 (-0.90%)
STOK : 11.66 (+3.64%)
Why Shares of Stoke Therapeutics Plummeted Tuesday

The company's shares fell after it released early trial results on its lead therapy.

STOK : 11.66 (+3.64%)
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91%

The consensus price target hints at a 102.9% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

STOK : 11.66 (+3.64%)
Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for

Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SYBX : 1.8700 (-2.09%)
STOK : 11.66 (+3.64%)
Stoke Therapeutics to Present at the BofA Securities Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 11.66 (+3.64%)
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STOK : 11.66 (+3.64%)
ACAD : 16.59 (-0.90%)
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 11.66 (+3.64%)
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...

STOK : 11.66 (+3.64%)
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

STOK : 11.66 (+3.64%)
MIRO : 3.39 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 13.08
2nd Resistance Point 12.56
1st Resistance Point 12.11
Last Price 11.66
1st Support Level 11.14
2nd Support Level 10.62
3rd Support Level 10.17

See More

52-Week High 16.40
Last Price 11.66
Fibonacci 61.8% 11.41
Fibonacci 50% 9.87
Fibonacci 38.2% 8.34
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar